Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRD1 | O95696 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873980 | 0.87 | GUSB (0.48) | GUSBPDE3BPDE3AKDR | |
| SCHEMBL874857 | 0.81 | GUSB (0.57) | GUSB | |
| SCHEMBL10222126 | 0.80 | ENPP1 (0.45) | PDE3BPDE3AKDR | |
| SCHEMBL15966710 | 0.77 | MAPT (0.55) | PDE5APARP1TRPV1 | |
| SCHEMBL874164 | 0.75 | GUSB (0.65) | GUSB | |
| SCHEMBL259473 | 0.74 | GUSB (0.67) | GUSBPARP1 | |
| SCHEMBL8499675 | 0.73 | TNKS (0.67) | GUSBPARP1 | |
| SCHEMBL874165 | 0.72 | GUSB (0.68) | GUSBPARP1 | |
| SCHEMBL11919793 | 0.72 | GUSB (0.55) | GUSB | |
| SCHEMBL873763 | 0.70 | GUSB (0.67) | GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | KADMON CORPORATION, LLC | 2015-12-03 | — | — | US | disclosed |
| EP-1865958-B1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8916576-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8357693-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120202793-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2012-08-09 | — | — | US | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | GUSB 895/4885PDE3B 121/4885PDE3A 103/4885 |
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | GUSB 895/4885PDE3B 121/4885PDE3A 103/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | GUSB 895/4885PDE3B 121/4885PDE3A 103/4885 |
| US-20120202793-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | GUSB 3229/4885PDE3B 309/4885PDE3A 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.